Lepp's big news was announced

Pharmaceutical Network December 4th, the first half of the profit, is 8 times the full year of 2019 December 1st, Saibai Blue device query the official website of the Shanghai Stock Exchange found that Lepu Medical subsidiary Beijing Lepu Diagnostic Technology Co., Ltd. officially issued a prospecto.
2017-2019, Lepu Diagnostics' revenue was RMB163 million, RMB226 million and RMB269 million, respectively, and net profit was RMB26.84 million, RMB32.77 million and RMB34.28 million, respectively, according to the prospecto.
to the first half of 2020, revenue and profit reached 523 million yuan and 273 million yuan, respectively, 1.9 times and 8.0 times the full-year revenue and profit for 2019.
understood that, prior to November 2 Lepu Medical issued an announcement that the proposed spin-off of its subsidiary Lepu Diagnostics to the Shanghai Stock Exchange Branch of the board listing.
part of the reason for the split is that Lepu Medical will further focus on the main industry, improve market competitiveness, is conducive to the company to highlight the main business, enhance independence.
on the other hand, Lepu Diagnostics will be independent of other business segments.
can be seen from Lepu Medical revenue, lepu diagnostic business increased under the impact of the new crown outbreak, but the main business of medicine and cardiovascular stents was affected.
prospects also show that since 2020, the outbreak of new crown pneumonia in the global large-scale outbreak, Lepu diagnostic new crown testing reagent products in the overseas market demand increased significantly, the first half of 2020 performance significantly improved, the new crown test reagent product revenue of 389.9786 million yuan, accounting for 74.66 percent of the main business revenue.
But the duration of such public health emergencies is uncertain, if the new crown outbreak is effectively controlled around the world, then Lepu Diagnostics new crown testing reagent product sales may fall, coupled with the recent introduction of new crown-related testing products, market competition intensified, product profit margins may also decline.
compared with its peers, the net profit is lower according to the prospecto, Lepu Diagnostics was established in 2008, the main business for in-body diagnostic reagents and equipment research and development, production and sales.
After more than ten years of development, Lepu Medical from the initial single collosome gold POCT reagent product development to the current collosome gold and fluorescent POCT, clotting diagnosis, biochemical diagnosis, chemical luminescent immunodiagnosis and molecular diagnosis five series of technology and product platform, is a small number of domestic technology and product coverage in-body diagnosis of many major areas of enterprises.
According to combing, domestic in-body diagnostic enterprises currently include Wanfu biological, egg-based biology, thermal scene biology, Anbiping, Minder biological and other enterprises, compared with the same industry compared to the company, Lepu Diagnostics 2019 issuer operating income is higher than hot-view biology, Minder biology and Sekoshid, net profit is relatively low.
source: Lepu Diagnostics prospecto according to the prospecto, Lepu Diagnostics is currently in a rapid development stage, with the continuous introduction of new products and market development capabilities continue to strengthen, its operating income and net profit is expected to achieve rapid growth.
For products on sale, Lepu Diagnostics has formed four large-scale molecular diagnostic products with collosine gold immunocolysis and fluorescent immunocoagulation heart markers, inflammatory series POCT, thrombosis trying to clott diagnosis, blood lipids, liver and kidney functions, and real-time fluorescence quantitative PCR instrument products as the core of molecular diagnostic products in production and sales of technology and product platforms.
Among them, POCT diagnostic series in 2019 to achieve sales revenue of nearly 100 million yuan, coagulation diagnostic series in 2019 to achieve sales revenue of more than 110 million yuan, bio-diagnostic series in 2019 to achieve sales revenue of more than 30 million yuan, cumulative sales revenue of nearly 100 million yuan, molecular diagnostic series fluorescence quantitative PCR instrument in 2020 cumulative sales of more than 1,500 units, become the fourth sales revenue of Lepu diagnostics up to 100 million yuan product line.
the global in-body diagnostics market was $64.8 billion in 2017 and is expected to reach $74.7 billion in 2020, according to Allied Market Research.
market segments, immunodiagnosis accounted for 23% of the global in-body diagnostics market size in 2018, bio-diagnostics accounted for 13% and molecular diagnostics accounted for 10%.
According to the China Medical Devices Blue Book (2019 edition), the market size of China's in-body diagnostics industry in 2018 was 60.4 billion yuan, up 18.43 percent year-on-year, and is expected to maintain an annual growth rate of more than 15 percent over the next decade.
With the continuous progress of technology, immunodiagnosis has replaced bio-diagnostics as the largest segment of the market in China's in-body diagnostics industry, accounting for 38% of the market share;
major markets occupied by multinational arms enterprises after many years of development, the global in-body diagnostic industry has entered a period of steady growth, mature industrial development, high market concentration.
prospectus shows that the global out-of-body diagnostics market has now formed a "four-plus-X" competitive landscape, with the first tier being the "big four" of the industry represented by Roche, Abbott, Danaher and Siemens.
second tier includes companies such as Thermo Fisher Technologies, Becton Dickinson of the United States and Sysmex of Japan.
2017, the top 10 companies in the global in-body diagnostics market achieved sales of $38,984 million, accounting for about 74% of the global market share, with a clear competitive advantage, according to Evaluate MedTech.
For the domestic market, the international giants of the in-body diagnostic industry occupy a relatively monopoly position in the high-end domestic in-body diagnostic market with their advantages in products, technology and services, especially in the domestic three-tier hospitals and other markets have a high market share.
domestic in-body diagnostic enterprises due to the relatively low level of technology and overall product quality, generally small scale, single product line, weak competitiveness, mainly occupy the secondary hospital and primary hospital market.
The domestic in-body diagnostic market starts late compared with developed countries such as Europe and the United States, the industry concentration is low, the majority of domestic in-body diagnostic reagent manufacturers are small and medium-sized enterprises, generally small in size, research and development capabilities and market competitiveness is weak.
of the 8th prospectos, the domestic in-body diagnostic industry is faced with three main problems: First, small enterprises, high-end products and markets are monopolized by multinational enterprises.
According to China Pharmaceutical Network data, China's in-body diagnostic production and research and development enterprises more than 1,000, in 2018 domestic enterprises revenue scale is less than 5 billion yuan, and in-body diagnostic multinational Danaher company in 2018 to achieve operating income of nearly 20 billion U.S. dollars.
second, product homogenization, the degree of competition is increasing.
from the end of the product to the end of the service, China's in-body diagnostic field of a large number of participants, the industry competition is fierce.
in the future, under the background of medical insurance fee control, homogenized products and business models will lead to more intense competition in the industry, which will adversely affect the profitability and operational ability of enterprises.
, research and development investment is insufficient, the core technology is relatively backward.
In-body diagnostic multinational enterprises with high investment in research and development and rich product layout to form technical barriers, domestic enterprises due to small and decentralized, in the research and development investment is seriously inadequate, resulting in insufficient innovation capacity, it is difficult to form new principles, new methods based on original technology and products.
At the same time, it is undeniable that in recent years, China's in-body diagnostic reagent market demand growth is rapid, the domestic larger in-body diagnostic enterprises seize the opportunity, by virtue of closer to the local market and cost-effective advantages, expanding market share, in some sub-sectors gradually began to break the market pattern dominated by imported products, and gradually emerged a number of strong, able to compete with international giants of local leading enterprises.
。